Genetic Analysis AS (FRA:8V8) LT-Debt-to-Total-Asset: 0.18 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:8V8 Genetic Analysis AS FRA:8V8
39 GF Score
Price €0.04
GF Value €0.04
! 4 Warning Signs
View Full Analysis

What is Genetic Analysis AS LT-Debt-to-Total-Asset?

Genetic Analysis AS FRA:8V8 -3.24% 39 LT-Debt-to-Total-Asset is 0.18 as of Mar. 2026. GuruFocus rates FRA:8V8 with a GF Score™ of 39/100 and a GF Value™ of €0.04. The stock has 4 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Genetic Analysis AS's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.18.

Genetic Analysis AS's long-term debt to total assets ratio declined from Mar. 2025 (0.21) to Mar. 2026 (0.18). It may suggest that Genetic Analysis AS is progressively becoming less dependent on debt to grow their business.

Genetic Analysis AS  (FRA:8V8) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Genetic Analysis AS LT-Debt-to-Total-Asset Related Terms

Genetic Analysis AS LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Genetic Analysis AS's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genetic Analysis AS LT-Debt-to-Total-Asset Chart

Genetic Analysis AS Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial 0.02 0.11 0.10 0.19 0.12

Genetic Analysis AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.21 0.14 0.16 0.12 0.18
FRA:8V8
39GF Score
Genetic Analysis AS FRA:8V8
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genetic Analysis AS LT-Debt-to-Total-Asset Calculation

Genetic Analysis AS's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=0.541/4.432
=0.12

Genetic Analysis AS's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=0.781/4.407
=0.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.18 mean?
Genetic Analysis AS (FRA:8V8) has a LT-Debt-to-Total-Asset of 0.18 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Genetic Analysis AS and its competitors.
Is Genetic Analysis AS's LT-Debt-to-Total-Asset too high?
Genetic Analysis AS's current LT-Debt-to-Total-Asset is 0.18. Overall, Genetic Analysis AS has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Genetic Analysis AS's LT-Debt-to-Total-Asset compare to TMO and DHR?
Genetic Analysis AS's LT-Debt-to-Total-Asset of 0.18 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Medical Diagnostics & Research company?
A good LT-Debt-to-Total-Asset depends on the Medical Diagnostics & Research industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Genetic Analysis AS and its competitors. Genetic Analysis AS's current LT-Debt-to-Total-Asset is 0.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetic Analysis AS stock overvalued right now?
Genetic Analysis AS (FRA:8V8) has a current LT-Debt-to-Total-Asset of 0.18. The stock's GF Value™ is €0.04, compared to a current price of €0.04 — trading 4.5% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.18. Genetic Analysis AS's overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Genetic Analysis AS (FRA:8V8), the current LT-Debt-to-Total-Asset is 0.18 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genetic Analysis AS (FRA:8V8) Overvalued in 2026?

Based on GuruFocus' analysis, Genetic Analysis AS stock appears to be overvalued. The current stock price of €0.04 is trading 4.5% above its estimated GF Value™ of €0.04.

Key valuation signals for FRA:8V8:

  • LT-Debt-to-Total-Asset: 0.18
  • GF Value™: €0.04 vs. price of €0.04 (4.5% above fair value)
  • GF Score™: 39/100 with 4 warning signs

No single metric tells the full story. See the FRA:8V8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Genetic Analysis AS Business Description

Other Exchanges GEAN:Sweden
Address Ulvenveien 80, Oslo, NOR, 0581
Genetic Analysis AS is a research-driven diagnostic company dedicated to delivering diagnostic solutions to the growing human microbiota market. It is providing a CE-marked gut microbiota analysis for testing bacterial imbalance in IBS and IBD patients. Geographically, it operates in the USA, Europe, and the Rest of the world. Geographically, the company sells products in the USA, Europe, and the rest of the world. The majority of its revenue is generated from the USA. The GA-map technology platform and product portfolio are currently used across three main market segments: Clinical diagnostics, research (academic and industry), and Consumer Health.
39GF Score

Get the complete analysis for FRA:8V8

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.04
Price
€0.04
GF Value